AVTX vs. MIRA, MBRX, ELAB, GHSI, ABVC, MNPR, AKTX, AEZS, ADXN, and NCNA
Should you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include MIRA Pharmaceuticals (MIRA), Moleculin Biotech (MBRX), Elevai Labs (ELAB), Guardion Health Sciences (GHSI), ABVC BioPharma (ABVC), Monopar Therapeutics (MNPR), Akari Therapeutics (AKTX), Aeterna Zentaris (AEZS), Addex Therapeutics (ADXN), and NuCana (NCNA). These companies are all part of the "pharmaceutical preparations" industry.
Avalo Therapeutics (NASDAQ:AVTX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, community ranking, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
Avalo Therapeutics received 5 more outperform votes than MIRA Pharmaceuticals when rated by MarketBeat users.
In the previous week, MIRA Pharmaceuticals had 6 more articles in the media than Avalo Therapeutics. MarketBeat recorded 10 mentions for MIRA Pharmaceuticals and 4 mentions for Avalo Therapeutics. MIRA Pharmaceuticals' average media sentiment score of -0.23 beat Avalo Therapeutics' score of -0.98 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.
MIRA Pharmaceuticals has a net margin of 0.00% compared to Avalo Therapeutics' net margin of -1,639.50%. MIRA Pharmaceuticals' return on equity of -293.51% beat Avalo Therapeutics' return on equity.
MIRA Pharmaceuticals has lower revenue, but higher earnings than Avalo Therapeutics.
87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 0.2% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Avalo Therapeutics beats MIRA Pharmaceuticals on 6 of the 11 factors compared between the two stocks.
Get Avalo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Avalo Therapeutics Competitors List
Related Companies and Tools
